BCL-2 Immunohistochemical Evaluation in B-Cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Before Treatment with Fludarabine and 2-Chloro-Deoxy-Adenosine-Reference-Cited by-同舟云学术

BCL-2 Immunohistochemical Evaluation in B-Cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Before Treatment with Fludarabine and 2-Chloro-Deoxy-Adenosine

Published:1998-01 Issue:5-6 Volume:28 Page:567-572
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zaja Francesco,Diloreto Carla,Amoroso Vito,Salmaso Flavia,Russo Domenico,Silvestri Federico,Fanin Renato,Damiani Daniela,Infanti Laura,Mariuzzi Laura,Beltrami Carlo Alberto,Baccarani Michele

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199809058365

Reference31 articles.

1. Bcl-2 initiates a new category of oncogenes: regulators of cell death

2. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

3. Molecular Analysis of the T(14;18) Chromosomal Translocation in Malignant Lymphomas

4. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group;Cancers;2024-06-10

2. BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism;Lymphatics;2024-03-28

3. Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies;American Journal of Hematology;2024-03-05

4. BCL2 Inhibition in Refractory Hairy-Cell Leukemia;New England Journal of Medicine;2023-05-25

5. Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia;New England Journal of Medicine;2023-03-09